Based on the Amylyx Pharmaceuticals Inc stock forecast from 2 analysts, the average analyst target price for Amylyx Pharmaceuticals Inc is USD 11.50 over the next 12 months. Amylyx Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amylyx Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Amylyx Pharmaceuticals Inc’s stock price was USD 3.74. Amylyx Pharmaceuticals Inc’s stock price has changed by +9.36% over the past week, +6.86% over the past month and -76.83% over the last year.
No recent analyst target price found for Amylyx Pharmaceuticals Inc
No recent average analyst rating found for Amylyx Pharmaceuticals Inc
Company Overview Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Read Less
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor compos...Read More
Frequently Asked Questions About Amylyx Pharmaceuticals Inc (AMLX) Stock
Based on ratings from 2 analysts Amylyx Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMLX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMLX is USD 11.50 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMLX stock's Price/Earning ratio is 2.51.
Our analysis grades AMLX stock's Price / Earning ratio at D-. This means that AMLX stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AMLX may be fairly valued for its sector
The last closing price of AMLX's stock was USD 3.74.
The most recent market capitalization for AMLX is USD 0.31B.
Based on targets from 2 analysts, the average taret price for AMLX is projected at USD 11.50 over the next 12 months.
This means that AMLX's stock price may go up by +207.49% over the next 12 months.
We can't find any ETFs which contains Amylyx Pharmaceuticals Inc's stock.
As per our most recent records Amylyx Pharmaceuticals Inc has 384 Employees.
Amylyx Pharmaceuticals Inc's registered address is 43 Thorndike Street, Cambridge, MA, United States, 02141.
You can get more information about it from Amylyx Pharmaceuticals Inc's website at https://amylyx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Amylyx Pharmaceuticals Inc (AMLX) Stock
Based on ratings from 2 analysts Amylyx Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMLX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMLX is USD 11.50 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMLX stock's Price/Earning ratio is 2.51.
Our analysis grades AMLX stock's Price / Earning ratio at D-. This means that AMLX stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AMLX may be fairly valued for its sector
The last closing price of AMLX's stock was USD 3.74.
The most recent market capitalization for AMLX is USD 0.31B.
Based on targets from 2 analysts, the average taret price for AMLX is projected at USD 11.50 over the next 12 months.
This means that AMLX's stock price may go up by +207.49% over the next 12 months.
We can't find any ETFs which contains Amylyx Pharmaceuticals Inc's stock.
As per our most recent records Amylyx Pharmaceuticals Inc has 384 Employees.
Amylyx Pharmaceuticals Inc's registered address is 43 Thorndike Street, Cambridge, MA, United States, 02141.
You can get more information about it from Amylyx Pharmaceuticals Inc's website at https://amylyx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMLX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
